Today's Clinical Lab - News, Editorial and Products for the Clinical Laboratory
Vector illustration of a pair of female and male researchers hold a DNA double helix sequence showing gene therapy.
The trial demonstrated the safety of a gene therapy target in patients with high-grade glioblastoma.
iStock, sorbetto

Gene Therapy for Glioblastoma Shows Promise in Phase 1 Trial

In a first-in-human trial in patients with recurrent glioblastoma, an oncolytic virus treatment safely extended survival

Brigham and Women's Hospital
Published:Oct 18, 2023
|3 min read
Register for free to listen to this article
Listen with Speechify

Glioblastoma (GBM) is notoriously resistant to treatment, with recurrent GBM associated with survival of less than 10 months. Immunotherapies have not been effective for an aggressive brain cancer like GBM, in part because the tumor’s surrounding environment is almost inaccessible to the body’s immune system. 

To convert this immunosuppressive environment into one amenable to an immune response, investigators from Brigham and Women’s Hospital (BWH), a founding member of the Mass General Brigham healthcare system, engineered a novel oncolytic virus that can infect cancer cells and stimulate an anti-tumor immune response. Results, published in Nature, demonstrated the safety and preliminary efficacy of the novel gene therapy approach in high-grade glioma patients, with prolonged survival in a subgroup of recurrent GBM patients immunologically “familiar” with the virus.

“GBM has an aggressive effect in part because of a milieu of immunosuppressive factors surrounding the tumor, which enable the tumor’s growth by preventing the immune system from entering and attacking it,” said corresponding author E. Antonio Chiocca, MD, PhD, chair of the BWH Department of Neurosurgery. “This study showed that with a virus we designed, we can reshape this ‘immune desert’ into a pro-inflammatory environment.”

This Phase I, first-in-human trial examined the safety of an oncolytic virus, called CAN-3110, which was designed and subjected to preclinical testing by researchers at BWH and licensed to Candel Therapeutics as the trial was ongoing.

How does the oncolytic virus function?

The cancer-attacking virus is an oncolytic herpes simplex virus (oHSV), which is the same type of virus used in a therapy approved for the treatment of metastatic melanoma. Unlike other clinical oHSVs, this therapy includes the ICP34.5 protein-coding gene, which is often excluded from clinical oHSVs because it causes human disease in unmodified forms of the virus. 

However, the researchers hypothesized that this gene may be necessary to trigger a robust, pro-inflammatory response necessary for attacking the tumor. Therefore, they designed a version of the oHSV1 that contains the ICP34.5 gene but is also genetically “programmed” to not attack healthy brain cells.

Overall, the trial demonstrated the safety of CAN-3110 in 41 patients with high-grade gliomas, including 32 with recurrent GBM. The most serious adverse events were seizures in two participants. 

Notably, 66 percent of the patients with GBM with preexisting antibodies to the HSV1 virus had a median overall survival of 14.2 months. In patients with preexisting antibodies, the researchers saw markers of several changes in the tumor microenvironment associated with immune activation. They hypothesize that the presence of HSV1 antibodies resulted in a rapid immune response to the virus, which brought more immune cells to the tumor and increased the levels of inflammation in the tumor microenvironment.

After CAN-3110 treatment, the investigators also observed an increase in the diversity of the T-cell repertoire, suggesting that the virus induces a broad immune response, perhaps by eliminating tumor cells resulting in the release of cancer antigens. These immunological changes after treatment were also shown to be associated with improved survival.

The plan ahead

Going forward, the researchers plan to complete prospective studies to further investigate the effectiveness of the oncolytic virus in patients who do and do not have antibodies to HSV1. Having demonstrated the safety of one viral injection, they are proceeding to test the safety and efficacy of up to six injections over four months, which, like multiple rounds of vaccination, may increase the effectiveness of the therapy. The new, six-injection trial is funded by Break Through Cancer.

“Almost no immunotherapies for GBM have been able to increase immune infiltration to these tumors, but the virus studied here provoked a very reactive immune response with infiltration of tumor-killing T cells,” Chiocca said. “That’s hard to do with GBM, so our findings are exciting and give us hope for our next steps.”

- This press release was originally published on the Brigham and Women’s Hospital website